Brokerages Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Target Price at $18.58

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $18.5833.

ATEC has been the subject of a number of analyst reports. Canaccord Genuity Group lowered their target price on shares of Alphatec from $25.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Wells Fargo & Company decreased their price objective on Alphatec from $28.00 to $14.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Barclays dropped their price objective on Alphatec from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Finally, TD Cowen reduced their target price on Alphatec from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th.

Insider Activity

In other Alphatec news, COO Scott Lish sold 260,535 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the sale, the chief operating officer directly owned 815,704 shares in the company, valued at approximately $10,033,159.20. This trade represents a 24.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Sponsel sold 163,452 shares of Alphatec stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $12.52, for a total transaction of $2,046,419.04. Following the transaction, the executive vice president directly owned 504,932 shares in the company, valued at approximately $6,321,748.64. This represents a 24.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 629,189 shares of company stock worth $7,801,589 over the last three months. Company insiders own 13.48% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Securities Group LLC bought a new position in shares of Alphatec during the first quarter worth about $29,000. Aster Capital Management DIFC Ltd bought a new position in shares of Alphatec in the 3rd quarter valued at about $34,000. Osterweis Capital Management Inc. acquired a new position in Alphatec during the second quarter worth approximately $37,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Alphatec by 157.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 1,571 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Alphatec in the third quarter valued at $73,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Performance

Alphatec stock opened at $7.66 on Wednesday. The company has a market cap of $1.18 billion, a PE ratio of -9.34 and a beta of 0.96. The company has a current ratio of 1.90, a quick ratio of 1.12 and a debt-to-equity ratio of 40.35. Alphatec has a 1 year low of $6.82 and a 1 year high of $23.29. The company’s 50-day moving average is $10.76 and its two-hundred day moving average is $15.51.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.21). The business had revenue of $192.11 million for the quarter, compared to analyst estimates of $197.51 million. Alphatec had a negative return on equity of 1,183.84% and a negative net margin of 15.93%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.35) EPS. Equities analysts anticipate that Alphatec will post -0.44 earnings per share for the current year.

Alphatec News Summary

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Alphatec and reiterated a $24 price target, while still projecting long-term EPS improvement to $0.88 in FY2028 and $1.00 in FY2029. HC Wainwright estimates and rating update
• Neutral Sentiment: Analysts at HC Wainwright lowered near-term earnings estimates for Q2 2026 and Q3 2026, but also raised some longer-range forecasts, indicating a mixed outlook rather than a full shift in sentiment. HC Wainwright earnings estimate changes
• Neutral Sentiment: Multiple articles recapped that Alphatec was weaker after its latest earnings-related reaction, suggesting investors are still digesting the company’s recent operating performance and sector backdrop. Street reaction to Alphatec post earnings
• Negative Sentiment: Several law firms announced or promoted securities fraud investigations into Alphatec following its May 5 earnings release, which can weigh on investor confidence and raise overhang risk for the shares. Howard G. Smith securities investigation
• Negative Sentiment: Another note highlighted a price target cut to $18.95, reinforcing a more cautious near-term view from the market. Price target decreased to 18.95

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.